Stem Cell Therapy Market

Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Surgery, and aGVHD), Cell Source (Adipose tissue, Bone Marrow, Neural, Embryo/Cord Blood derived, iPSCs) - Global Forecasts to 2021

Report Code: BT 5049 Oct, 2019, by marketsandmarkets.com
Updated date -

[120 Pages Report] The global stem cell therapy market is estimated to reach USD 145.8 million by 2021, growing at a CAGR of 11.0% during the forecast period. Growing awareness related to the therapeutic potency of stem cells in disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for stem cell research and development, identification of new stem cell lines, and developments in infrastructure for Stem Cell Banking and processing are some key factors driving the growth of this market. Furthermore, countries such as Japan, South Korea, and China offer new growth opportunities for market players. On the other hand, unclear regulatory guidelines related to the development & commercialization of stem cell therapy products and socio-ethical issues related to the adoption of ESCs in disease treatment are the major factors restraining the market growth.

The base year considered for the study is 2015, and the forecast has been provided for the period between 2016 and 2021.

Market Dynamics

Growing awareness of the therapeutic potency of stem cells in effective disease management

Stem cell therapy has brought significant and revolutionary changes in the field of disease management strategies and patient care. These products offer effective treatment of conditions such as cancer, aGVHD, and vascular diseases. In recent years, stem cell therapy has been considered as a promising candidate in the field of regenerative medicine for the replacement or regeneration of damaged tissues.

There is growing awareness in the industry related to the therapeutic potency of stem cells for effective disease management. This is supported by the rising number of clinical trials and successful research studies that aim to validate the therapeutic potential of stem cell-based products. Among the recent clinical trials are the following:

  • Xuzhou Medical University (China) initiated an interventional study in 2016 (last updated in October 2016). This study is aimed at the therapeutic evaluation of adipose-derived stem cells or fat cells for facial rejuvenation.
  • The Affiliated Hospital of Academy of Military Medical Sciences (China) initiated an interventional phase 1 and phase 2 study in collaboration with Ivy Institute of Stem Cells Co. Ltd (China) in 2015 (last updated in March 2016). The study is aimed at testing the safety and efficacy of umbilical cord-derived mesenchymal stem cells (UC-MSCs) for treatment of patients with chronic heart ischemia cohort.
  • Celal Bayar University (Turkey) initiated an interventional phase 1 study in collaboration with the Scientific and Technological Research Council (Turkey) and Acýbadem Labcell (Turkey) in 2016 (last updated in July 2016). The study is aimed at determining the safety and efficacy of mesenchymal stem cells derived from autologous adipose tissue for the treatment of chronic autoimmune urticaria.
  • Asan Medical Center (South Korea) initiated an interventional phase 2 study in 2014 (last updated in January 2016) aimed at determining the efficacy and safety of mesenchymal stem cell in acute severe respiratory failure.
  • Stemedica Cell Technologies, Inc. (U.S.) initiated an interventional phase 2 study in collaboration with Stemedica International SA (Switzerland) in 2016 (last updated in October 2016). The study is aimed at assessing the safety, tolerability, and efficacy of ischemia-tolerant allogeneic human mesenchymal stem cells (manufactured by Stemedica) in patients having mild-to-moderate dementia due to Alzheimer's disease.
  • The University of Pittsburgh (U.S.) initiated an interventional phase 1 and phase 2 study in collaboration with Miltenyi Biotec GmbH (Germany) in 2008 (last updated in February 2016). The study is aimed at assessing the safety of high-dose immunotherapy    followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSCs) for the treatment of severe Crohn's disease.

As many as 5,888 active NIH-registered stem cell-based clinical trials are being conducted worldwide. These clinical trials are expected to augment the consumer adoption and physician preference for stem cell therapies across major markets. This is expected to drive the demand for stem cell therapy products worldwide during the forecast period.

Unclear regulatory guidelines for product development and commercialization

As compared to drug-based therapeutics, there are a number of policy and regulation-related considerations related to the use of stem cell therapy Before stem cell-based products can be commercialized, manufacturers need to ensure and prove the safety and efficacy of said products (through contamination testing; toxicity testing; fulfillment of cGMP, standards, and controls; preclinical studies; and clinical studies).

In the EU, stem cell therapy products are included under the Advanced Therapy Medicinal Products (ATMP) category. Regulations for ATMP, passed in 2007, came into effect in December 2008. These regulations and guidelines are based on three main directives—Directive 2003/63/EC, which states specific requirements for cell therapy products; Directive 2001/20/EC, which emphasizes conducting clinical trials and sets specific requirements for clinical trials; and Directive 2004/23/EC, which establishes the safety and quality standards for harvesting, testing, storage, processing, and distribution of human tissues and cells (Source: EMA). The Committee for Advanced Therapies within the European Medicines Agency (EMA) monitors the safety and efficacy of ATMPs and provides marketing approval to the product. As of December 2016, the committee has approved only one stem cell therapy product.

In the U.S., the Center for Biologics Evaluation and Research (CBER) (a division of the FDA) is responsible for regulating stem cell therapy products. Regulations in the U.S. are based on three sections—IND regulations (21 CFR 312); biologics regulations (21 CFR 600); and cGMP (21 CFR 211) (Source: U.S. FDA). Stem cell-based products that are minimally manipulated, labeled, and not combined with a drug or device do not require FDA approval for marketing; however, they must follow cGMP guidelines. Hence, there is significant scrutiny on products in the U.S., which has led to the limited commercialization of stem cell therapy products in the country.

However, emerging countries are yet to develop a well-defined regulatory framework for the commercialization of stem cell-based products.

  • The regulatory process of the Korean Ministry of Food and Drug Safety (MFDS) is fast and less stringent as compared to other developed countries. In the last five years, the Ministry of Food and Drug Safety (MFDS) of South Korea approved four stem cell drugs and more than 100 clinical trials for stem cell drugs (Source: MFDS, South Korea).
  • In India, the Indian Council of Medical Research (ICMR) established the ‘Ethical Guidelines for Biomedical Research on Human subjects’ in 2006. In 2007, the ICMR and Department of Biotechnology (DBT) laid down ‘Guidelines for Stem Cell Research and Therapy’, which focuses on the registered and regulated use of stem cell lines created or imported in India. In 2008, the Central Drugs Standard Control Organization (CDSCO) released a guidance document on the submission requirements for new drug approvals for biotechnological/biological products, which requires the manufacturer to submit the application in Common Technical Document (CTD) format. However, there is no specific form available for the grant/renewal of license of manufacturing of stem cell-based products. This lack of clear regulatory guidelines for product development and commercialization restricts market growth to a certain extent.

Stem cell R&D is also associated with socio-ethical and moral issues. Due to different cultural views across various countries, it is difficult to formulate a single global policy or law to govern stem cell research. Subsequently, the rules and regulations laid down by each country provide a distinct set of variations; this situation has considerably affected both stem cell research as well as government funding patterns for the same. Concerns related to the availability of funding for stem cell research can lead to increased costs for product development and commercialization.

The cardiovascular diseases application segment is expected to witness fastest growth in stem cell therapy market during the forecast period

On the basis of therapeutic applications, the market is classified into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, gastrointestinal diseases, surgery, and other therapeutic applications. The musculoskeletal disorders segment dominates the global stem cell therapy market in 2016, owing to factors such as larger number of commercialized stem cell therapy products for the treatment of musculoskeletal disorders and the increasing prevalence of musculoskeletal disorders (coupled with the growth in geriatric population). However, the cardiovascular diseases segment is expected to register the highest CAGR in the forecast period. Growth in this application segment is attributed to the growing demand for safe and effective treatment options for cardiovascular disease and the growing number of cardiovascular-related stem cell researches across the globe.

The following are the major objectives of the study:

  • To define, describe, and forecast the global market on the basis of type, therapeutic application, cell source, and region
  • To provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, growth opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market
  • To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for major market players
  • To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia-Pacific, and RoW
  • To strategically profile the key market players and comprehensively analyze their market shares and core competencies2
  • To track and analyze competitive developments such as new product approvals and launches; expansions; and partnerships, agreements, and collaborations in the stem cell therapy market

During this research study, major players operating in the market in various regions have been identified, and their offerings, regional presence, and distribution channels have been analyzed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as company annual reports, investor presentations, Hoovers, Bloomberg BusinessWeek, and Factiva, along with primary respondents. The entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) pertaining to the market. The figure below shows the breakdown of the primaries on the basis of the company type, designation, and region considered during the research study.

Stem Cell Therapy Market-Breakdown of Primary Participants

To get more details on this report, Download PDF Brochure

Some of the major players in the stem cell therapy market include Osiris Therapeutics, Inc. (US), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l. (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (US), RTI Surgical, Inc. (US), and AlloSource (US) among others.

Target Audience:

  • Stem Cell Therapeutic Product Manufacturing Companies
  • Healthcare Service Providers (Including Hospitals and Diagnostic Centers)
  • Pharmaceutical Product Manufacturing Companies
  • National and Regional Research Boards and Organizations
  • Research and Development (R&D) Companies
  • Clinical Research Organizations (CROs)
  • Research Laboratories and Academic Institutes
  • Market Research and Consulting Firms
  • Stem Cell Associations and Organizations

Report Scope:

Stem Cell Therapy Market, by Type

  • Allogeneic Stem Cell Therapy, by Application
  • Musculoskeletal disorders
  • Wounds and Injuries
  • Surgeries
  • acute Graft-Versus-Host Disease (aGVHD)
  • Other Applications
  • Allogeneic Stem Cell Therapy, by Application
  • Wounds and Injuries
  • Cardiovascular Diseases
  • Gastrointestinal Diseases
  • Other Applications

Stem Cell Therapy Market, by Therapeutic Application

  • Musculoskeletal disorders
  • Wounds and Injuries
  • Cardiovascular Diseases
  • Surgeries
  • Gastrointestinal Diseases
  • Other Therapeutic Applications

Stem Cell Therapy Market, by Cell Source

  • Adipose Tissue-derived Mesenchymal Stem Cells
  • Bone Marrow-derived Mesenchymal Stem Cells
  • Cord Blood/Embryonic Stem Cells
  • Other Cell Sources

Stem Cell Therapy Market, by Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Critical questions which the report answers

  • Stem cell based treatments are still in research/nascent phased; how their market/commercial usage will evolve in coming decade?
  • What are key cell lines those are currently being used commercially for clinical treatment; which are key geographic areas driving revenue growth for these products?
  • What is current regulatory scenario for clinical usage of Stem cell based treatments across key healthcare market?
  • What is development pipeline of key stem cell lines for major product manufacturers during past 4-5 years?

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the global stem cell therapy market report:

Product Analysis

  • Product Matrix which gives a detailed comparison of the product portfolios of the top five companies

Geographical Analysis

  • Further breakdown of the North American stem cell therapy market into the US and Canada
  • Further breakdown of the European market into the UK, Germany, France, and Rest of Europe

Company Information

  • Detailed analysis and profiling of additional market players (Up to 5)

The global stem cell therapy market is expected to reach USD 145.8 million by 2021, growing at a CAGR of 11.0% during the forecast period. Factors such as the growing awareness related to the therapeutic potency of stem cells in disease management, ongoing development of advanced genome-based cell analysis techniques, increasing public-private investments for stem cell research and product development, identification of new stem cell lines, and developments in infrastructure for stem cell banking and processing are driving the growth of the global stem cell therapy market. However, factors such as unclear regulatory guidelines related to the development & commercialization of stem cell therapy products and socio-ethical issues related to the adoption of ESCs in disease treatment are restraining the growth of this market. In addition to this, technical limitations related to production scale-up pose a key challenge for players operating in this market.

On the basis of type, the global market is divided into two major categories, namely, allogeneic stem cell therapy and autologous stem cell therapy. On the basis of application, the allogeneic market is further divided into—musculoskeletal disorders, wounds and injuries, surgeries, acute Graft-Versus-Host Disease (aGVHD), and other applications.
On the basis of application, the autologous stem cell therapy market is categorized into—wounds and injuries, cardiovascular diseases, gastrointestinal diseases, and other applications. The allogenic stem cell therapy segment is expected to grow at the highest CAGR during the forecast period, owing to the rising commercialization of allogeneic stem cell therapy products, wider therapeutic applications of allogeneic stem cells, easy production scale-up process, and growing number of clinical trials related to allogeneic stem cell therapies.

On the basis of region, this market is classified into North America, Europe, Asia-Pacific, and the Rest of the World. In 2016, the global market is expected to be dominated by North America. Also, this region is expected to be the fastest-growing region during the forecast period. Factors such as growing awareness related to the therapeutic potency of stem cells, increasing number of clinical trials for stem cell-based products, and increasing public-private funding & research grants are driving the growth of this market in the North American region.

Stem Cell Therapy Market-By Region

To get more details on this report, Request FREE Sample

Product Launches: Key Strategy Adopted by the Major Players in this Market

New product launches and approvals are the key growth strategies adopted by major players to strengthen their positions in the global stem cell therapy market. Moreover, strategies such as expansions as well as partnerships and agreements were also adopted by several market players to expand their R&D capabilities and geographic presence in the global market.

As of 2015, Osiris Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l. (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (U.S.), RTI Surgical, Inc. (U.S.), and AlloSource (U.S.) were some of the key players operating in the global Stem Cell Therapy Market.

Critical questions the report answers:

  • Stem cell based treatments are still in research/nascent phased; how their market/commercial usage will evolve in coming decade?
  • What are key cell lines those are currently being used commercially for clinical treatment; which are key geographic areas driving revenue growth for these products?
  • What is current regulatory scenario for clinical usage of Stem cell based treatments across key healthcare market?
  • What is development pipeline of key stem cell lines for major product manufacturers during past 4-5 years?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Contents

1 Introduction (Page No. - 15)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Geographic Scope
           1.3.3 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 19)
    2.1 Research Data
           2.1.1 Secondary Data
                    2.1.1.1 Key Data From Secondary Sources
           2.1.2 Primary Data
                    2.1.2.1 Key Data From Primary Sources
                    2.1.2.2 Breakdown of Primaries
    2.2 Market Size Estimation
           2.2.1 Bottom-Up Approach
           2.2.2 Top-Down Approach
    2.3 Market Breakdown and Data Triangulation
    2.4 Research Assumptions

3 Executive Summary (Page No. - 26)
    3.1 Introduction
    3.2 Conclusion

4 Premium Insights (Page No. - 30)
    4.1 Market Overview
    4.2 Regional Analysis: Market, By Type, 2016 vs 2021 (USD Million)
    4.3 Global Market, By Therapeutic Application, 2016–2021 (USD Million)
    4.4 Regional Analysis: Market, By Cell Source, 2016 vs 2021 (USD Million)

5 Market Overview (Page No. - 34)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Market Growth Drivers
                    5.2.1.1 Growing Awareness Related to the Therapeutic Potency of Stem Cells in Effective Disease Management
                    5.2.1.2 Development of Advanced Genome-Based Cell Analysis Techniques
                    5.2.1.3 Increasing Public-Private Investments for the Development of Stem Cell Therapies
                    5.2.1.4 Development in Infrastructure Related to Stem Cell Banking and Processing
           5.2.2 Market Restraints
                    5.2.2.1 Unclear Regulatory Guidelines for Product Development & Commercialization
                    5.2.2.2 Socio-Ethical Issues Related to the Use of Escs in Disease Treatment
           5.2.3 Market Growth Opportunities
                    5.2.3.1 Supportive Regulations Across Developing Countries
                    5.2.3.2 Emergence of Ipscs as an Effective Alternative to Escs
           5.2.4 Market Challenges
                    5.2.4.1 Technical Limitations Related to Production Scale-Up
    5.3 Regulatory Landscape
           5.3.1 North America
           5.3.2 Europe
           5.3.3 Asia-Pacific
           5.3.4 Rest of the World

6 Industry Insights (Page No. - 46)
    6.1 Introduction
    6.2 Supply Chain Analysis
           6.2.1 Key Stakeholders
           6.2.2 Key Influencers
    6.3 Pipeline Analysis
           6.3.1 Pipeline Analysis: Based on Phase of Clinical Study
           6.3.2 Pipeline Analysis: Based on Type
           6.3.3 Pipeline Analysis: Based on the Cell Line Used

7 Global Stem Cell Therapy Market, By Type (Page No. - 52)
    7.1 Introduction
    7.2 Allogeneic Stem Cell Therapy Market, By Application
           7.2.1 Musculoskeletal Disorders
           7.2.2 Wounds and Injuries
           7.2.3 Surgeries
           7.2.4 Acute Graft-Versus-Host Disease (AGVHD)
           7.2.5 Other Applications
    7.3 Autologous Market, By Application
           7.3.1 Wounds and Injuries
           7.3.2 Cardiovascular Diseases
           7.3.3 Gastrointestinal Diseases
           7.3.4 Other Applications

8 Global Stem Cell Therapy Market, By Therapeutic Application (Page No. - 65)
    8.1 Introduction
    8.2 Musculoskeletal Disorders
    8.3 Wounds and Injuries
    8.4 Cardiovascular Diseases
    8.5 Surgeries
    8.6 Gastrointestinal Diseases
    8.7 Other Applications

9 Global Stem Cell Therapy Market, By Cell Source (Page No. - 73)
    9.1 Introduction
    9.2 Adipose Tissue-Derived Mesenchymal Stem Cells
    9.3 Bone Marrow-Derived Mesenchymal Stem Cells
    9.4 Cord Blood/Embryonic Stem Cells
    9.5 Other Cell Sources

10 Stem Cell Therapy Market, By Region (Page No. - 78)
     10.1 Introduction
     10.2 North America
     10.3 Europe
     10.4 Asia-Pacific
     10.5 Rest of the World (RoW)

11 Competitive Landscape (Page No. - 92)
     11.1 Overview
     11.2 Market Ranking
     11.3 Strategic Benchmarking
             11.3.1 Product Development and Commercialization
     11.4 Competitive Scenario
     11.5 Recent Developments
             11.5.1 Product Launches and Approvals
             11.5.2 Expansions
             11.5.3 Agreements, Collaborations, and Partnerships

12 Company Profiles (Page No. - 98)
     12.1 Introduction
             12.1.1 Geographic Benchmarking
(Overview, Financials, Products & Services, Strategy, and Developments)*
     12.2 Osiris Therapeutics, Inc.
     12.3 Medipost Co., Ltd.
     12.4 Anterogen Co., Ltd.
     12.5 Pharmicell Co., Ltd.
     12.6 Holostem Terapie Avanzate Srl
     12.7 JCR Pharmaceuticals Co., Ltd.
     12.8 Nuvasive, Inc.
     12.9 RTI Surgical, Inc.
     12.10 Allosource

*Details on Overview, Financials, Product & Services, Strategy, and Developments Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. - 113)
     13.1 Insights of Industry Experts
     13.2 Discussion Guide
     13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
     13.4 Introducing RT: Real-Time Market Intelligence
     13.5 Available Customizations
     13.6 Related Reports
     13.7 Author Details


List of Tables (60 Tables)

Table 1 Few of the Recently Launched Cell Analysis Products (2015-2017)
Table 2 North America: Regulatory Landscape for Stem Cell Therapy (As of 2016)
Table 3 Europe: Regulatory Landscape for Stem Cell Therapy (As of 2016)
Table 4 Asia-Pacific: Regulatory Landscape for Stem Cell Therapy (As of 2016)
Table 5 RoW: Regulatory Landscape for Stem Cell Therapy (As of 2016)
Table 6 Global Market Size, By Type, 2014-2021 (USD Million)
Table 7 Global Allogeneic Stem Cell Therapy Market Size, By Application, 2014-2021 (USD Million)
Table 8 Global Allogeneic Market Size, By Region, 2014-2021 (USD Million)
Table 9 Allogeneic Stem Cell Therapy Market Size for Musculoskeletal Disorders, By Region, 2014-2021 (USD Million)
Table 10 Allogeneic Market Size for Wounds and Injuries, By Region, 2014-2021 (USD Million)
Table 11 Market Size for Surgeries, By Region, 2014-2021 (USD Million)
Table 12 Allogeneic Market Size for Acute Graft-Versus-Host Disease, By Region, 2014-2021 (USD Million)
Table 13 Allogeneic Stem Cell Therapy Market Size for Other Applications, By Region, 2014-2021 (USD Million)
Table 14 Global Autologous Market Size, By Application, 2014-2021 (USD Million)
Table 15 Global Autologous Market Size, By Region, 2014-2021 (USD Million)
Table 16 Autologous Market for Wounds and Injuries, By Region, 2014-2021 (USD Million)
Table 17 Market Size for Cardiovascular Diseases, By Region, 2014-2021 (USD Million)
Table 18 Autologous Market Size for Gastrointestinal Diseases, By Region, 2014-2021 (USD Million)
Table 19 Autologous Market Size for Other Applications, By Region, 2014-2021 (USD Million)
Table 20 Global Market Size, By Therapeutic Application, 2014-2021 (USD Million)
Table 21 Market Size for Musculoskeletal Disorders, By Region, 2014-2021 (USD Million)
Table 22 Market Size for Wounds and Injuries, By Region, 2014-2021 (USD Million)
Table 23 Market Size for Cardiovascular Diseases, By Region, 2014-2021 (USD Million)
Table 24 Market Size for Surgeries, By Region, 2014-2021 (USD Million)
Table 25 Market Size for Gastrointestinal Diseases, By Region, 2014-2021 (USD Million)
Table 26 Market Size for Other Applications, By Region, 2014-2021 (USD Million)
Table 27 Global Market Size, By Cell Source, 2014-2021 (USD Million)
Table 28 Market Size for Adipose Tissue-Derived MSCS, By Region, 2014-2021 (USD Million)
Table 29 Market Size for Bone Marrow-Derived MSCS, By Region, 2014-2021 (USD Million)
Table 30 Market Size for Cord Blood/Embryonic Stem Cells, By Region, 2014-2021 (USD Million)
Table 31 Market Size for Other Cell Sources, By Region, 2014-2021 (USD Million)
Table 32 Market Size, By Region, 2014-2021 (USD Million)
Table 33 North America: Market Size, By Type, 2014-2021 (USD Million)
Table 34 North America: Market Size, By Therapeutic Applications, 2014-2021 (USD Million)
Table 35 North America: Market Size, By Cell Source, 2014-2021 (USD Million)
Table 36 Europe: Market Size, By Type, 2014-2021 (USD Million)
Table 37 Europe: Market Size, By Therapeutic Application, 2014-2021 (USD Million)
Table 38 Europe: Market Size, By Cell Source, 2014-2021 (USD Million)
Table 39 Asia-Pacific: Market Size, By Type, 2014-2021 (USD Million)
Table 40 Asia-Pacific: Market Size, By Therapeutic Application, 2014-2021 (USD Million)
Table 41 Asia-Pacific: Stem Cell Therapy Market Size, By Cell Source, 2014-2021 (USD Million)
Table 42 RoW: Market Size, By Type, 2014-2021 (USD Million)
Table 43 RoW: Market Size, By Therapeutic Application, 2014-2021 (USD Million)
Table 44 RoW: Market Size, By Cell Source, 2014-2021 (USD Million)
Table 45 Top Product Launches and Approvals (2013–2016)
Table 46 Top Expansions (2013 – 2016)
Table 47 Top Agreements, Collaborations, and Partnerships (2013-2016)
Table 48 Osiris Therapeutics, Inc.: Products Offered
Table 49 Osiris Therapeutics, Inc.: Product Pipeline
Table 50 Medipost Co., Ltd.: Products Offered
Table 51 Medipost Co., Ltd.: Product Pipeline
Table 52 Anterogen Co., Ltd.: Products Offered
Table 53 Anterogen Co., Ltd.: Product Pipeline
Table 54 Pharmicell Co., Ltd.: Products Offered
Table 55 Pharmicell Co., Ltd.: Product Pipeline
Table 56 Holostem Terapie Avanzate Srl: Products Offered
Table 57 JCR Pharmaceuticals Co., Ltd.: Products Offered
Table 58 Nuvasive, Inc.: Products Offered
Table 59 RTI Surgical, Inc.: Products Offered
Table 60 Allosource: Products Offered


List of Figures (37 Figures)

Figure 1 Research Design
Figure 2 Bottom-Up Approach
Figure 3 Top-Down Approach
Figure 4 Data Triangulation
Figure 5 Assumptions for the Study
Figure 6 Allogeneic Stem Cell Therapy Dominates the Market in 2016
Figure 7 Musculoskeletal Disorders Commands the Largest Share of the Market in 2016
Figure 8 Adipose Tissue-Derived MSCS Will Continue to Dominate the Market Till 2021
Figure 9 Market Share, By Region
Figure 10 Emerging Countries Offer High-Growth Opportunities to Players in the Market
Figure 11 Allogeneic Stem Cell Therapy to Dominate the Global Market During Forecast Period
Figure 12 Musculoskelatal Disorders Segment to Dominate the Global Market During Forecast Period
Figure 13 Adipose Tissue-Derived Cell Source Segment to Dominate the Market During Forecast Period
Figure 14 Growing Public Awareness Related to Therapeutic Potency of Stem Cells is Augmenting the Market Growth During the Study Period
Figure 15 Market Players Prefer Both Direct & Indirect Distribution Strategies for Stem Cell Therapy Products Across Major Geographies
Figure 16 Majority of Stem Cell Therapy Candidate Products are in Preclinical Phase, Followed By Phase 1 & Phase 1/2
Figure 17 Allogeneic Stem Cell Therapy Pipeline Products Account for A Larger Share of the Overall Stem Cell Therapy Products Under Development
Figure 18 Allogeneic Stem Cell Therapy Pipeline Products: Based on Study Phases
Figure 19 Autologous Stem Cell Therapy Pipeline Products: Based on Study Phases
Figure 20 Bone Marrow-Derived Mesenchymal Stem Cells are Preferred for Stem Cell Therapy Development
Figure 21 Allogeneic Stem Cell Therapy to Dominate the Global Market Till 2021
Figure 22 Musculoskelatal Disorders to Dominate the Allogeneic Market Till 2021
Figure 23 Wounds and Injuries Market to Dominate the Autologous Stem Cell Therapy Market Till 2021
Figure 24 Musculoskelatal Disorders Segment to Dominate Global Market Till 2021
Figure 25 Adipose Tissue-Derived Mesenchymal Stem Cells to Dominate the Global Stem Cell Therapy Market Till 2021
Figure 26 North America: Market Snapshot
Figure 27 Europe: Market Snapshot
Figure 28 Asia Pacific: Market Snapshot
Figure 29 RoW: Market Snapshot
Figure 30 Global Market Ranking (2015)
Figure 31 Product Development and Commercialization: the Key Growth Strategy Adopted By Market Players (2013-2016)
Figure 32 Product Launches and Enhancements: Key Strategy Adopted By Majority of Key Players During Study Period
Figure 33 Geographic Revenue Mix of the Top Five Players (2015)
Figure 34 Medipost Co., Ltd.: Company Snapshot (2015)
Figure 35 JCR Pharmaceuticals Co., Ltd.: Company Snapshot (2015)
Figure 36 Nuvasive, Inc.: Company Snapshot (2015)
Figure 37 RTI Surgical, Inc.: Company Snapshot (2015)

To get more details on this report, Request FREE Sample


Request for detailed methodology, assumptions & how numbers were triangulated.

Please share your problem/objectives in greater details so that our analyst can verify if they can solve your problem(s).
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)
Report Code
BT 5049
Published ON
Oct, 2019
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Stem Cell Therapy Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

...

Digital Virtual Assistant - MarketsandMarkets

Home